SA515370289B1 - طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي - Google Patents

طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي

Info

Publication number
SA515370289B1
SA515370289B1 SA515370289A SA515370289A SA515370289B1 SA 515370289 B1 SA515370289 B1 SA 515370289B1 SA 515370289 A SA515370289 A SA 515370289A SA 515370289 A SA515370289 A SA 515370289A SA 515370289 B1 SA515370289 B1 SA 515370289B1
Authority
SA
Saudi Arabia
Prior art keywords
dosing regime
dosing
providing
regime
plasma protein
Prior art date
Application number
SA515370289A
Other languages
English (en)
Inventor
لويو-بازيلي ألكسندرا
ديكي سبوتس جيرالد
أوه ميونجشين
Original Assignee
باكسالتا إنكوربوريتد
باكسالتا جي ام بي اتش
تـاكيدا فـارماسيوتيكل كمبني ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52111779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA515370289(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by باكسالتا إنكوربوريتد, باكسالتا جي ام بي اتش, تـاكيدا فـارماسيوتيكل كمبني ليمتد filed Critical باكسالتا إنكوربوريتد
Publication of SA515370289B1 publication Critical patent/SA515370289B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20Supervised data analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30Unsupervised data analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20Probabilistic models
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30Prediction of properties of chemical compounds, compositions or mixtures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00Subject matter not provided for in other groups of this subclass
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Computing Systems (AREA)
  • Databases & Information Systems (AREA)
  • Physiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Probability & Statistics with Applications (AREA)

Abstract

يتعلق الاختراع الحالي بنظام وطريقة لتوفير نظام تجريع بروتين بلازما علاجي (therapeutic plasma protein dosing regimen) تتضمن تحديد، من خلال معالج (processor)، نمط دوائي حركي (pharmacokinetic profile) مُقدّر لمريض باستخدام نموذج Bayesian للأنماط الدوائية الحركية (pharmacokinetic profiles) من مرضى تم أخذ العينات منهم. تتضمن أيضا الطريقة والنظام التمثيليين تحديد نظام تجريع (dosing regimen) أول من أجل فاصل زمني لتجريع (dosing interval) محدد أول يتضمن (1) تجريع أول و(2) مستوى بروتين بلازما علاجي (therapeutic plasma protein) أول في المريض بمرور فترة زمنية اعتمادا على الأقل على النمط الدوائي الحركي (pharmacokinetic profile) وتحديد نظام تجريع (dosing regimen) ثان من أجل فاصل زمني لتجريع (dosing interval) محدد ثان يتضمن (1) تجريع ثان و(2) مستوى بروتين بلازما علاجي (therapeutic plasma protein) ثان في المريض بمرور فترة زمنية اعتمادا على الأقل على النمط الدوائي الحركي (pharmacokinetic profile). تتضمن إضافيا الطريقة والنظام التمثيليين عرض نظام التجريع (dosing regimen) الأول ونظام التجريع (dosing regi
SA515370289A 2013-06-20 2015-12-17 طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي SA515370289B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837421P 2013-06-20 2013-06-20
US201361840969P 2013-06-28 2013-06-28
US201361881214P 2013-09-23 2013-09-23

Publications (1)

Publication Number Publication Date
SA515370289B1 true SA515370289B1 (ar) 2022-02-02

Family

ID=52111779

Family Applications (2)

Application Number Title Priority Date Filing Date
SA521430246A SA521430246B1 (ar) 2013-06-20 2015-12-17 طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي
SA515370289A SA515370289B1 (ar) 2013-06-20 2015-12-17 طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SA521430246A SA521430246B1 (ar) 2013-06-20 2015-12-17 طريقة وجهاز لتوفير نظام تجريع عقار دوائي حركي

Country Status (23)

Country Link
US (1) US20140379629A1 (ar)
EP (3) EP3010681B1 (ar)
JP (4) JP2016526542A (ar)
KR (4) KR102296042B1 (ar)
CN (2) CN111508557B (ar)
AU (3) AU2014287706B2 (ar)
BR (3) BR122022000127A8 (ar)
CA (1) CA2915472C (ar)
CL (1) CL2015003641A1 (ar)
EA (1) EA037962B1 (ar)
ES (1) ES2882832T3 (ar)
GE (2) GEP20186882B (ar)
IL (3) IL279313B (ar)
MX (3) MX2015017878A (ar)
MY (2) MY176173A (ar)
NZ (1) NZ715216A (ar)
PH (1) PH12015502800B1 (ar)
PL (1) PL3010681T3 (ar)
SA (2) SA521430246B1 (ar)
SG (1) SG11201510515YA (ar)
UA (1) UA118109C2 (ar)
WO (1) WO2015006033A1 (ar)
ZA (1) ZA201600100B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987321B (zh) * 2011-12-13 2017-06-09 皇家飞利浦有限公司 用于基于结果质量的剂量优化的系统和方法
KR102370479B1 (ko) 2012-10-05 2022-03-04 다이앤 몰드 수학적 모형 함수로서의 환자-특이적 투여법용 의약
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2015154090A1 (en) 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
US11062797B2 (en) * 2014-10-10 2021-07-13 Continuous Precision Medicine Method and system for obtaining and using pharmacokinetic data in drug administration
SG10202009369SA (en) * 2015-04-09 2020-10-29 Diane Mould Systems and methods for patient-specific dosing
WO2017136583A1 (en) * 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
CA3020346A1 (en) * 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
JP6807015B2 (ja) * 2016-06-13 2021-01-06 ソニー株式会社 情報処理装置、情報処理方法、およびプログラム
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US20190365317A1 (en) * 2017-02-01 2019-12-05 Shire Human Genetic Therapies, Inc. Physiological sensing and therapeutic administration system and method
BE1027052A1 (fr) 2019-02-14 2020-09-07 Aardex Group Procede d'assistance a la prise ou a l'acte d'un traitement therapeutique
US10970651B1 (en) * 2019-12-02 2021-04-06 Sas Institute Inc. Analytic system for two-stage interactive graphical model selection
KR102420872B1 (ko) * 2020-12-18 2022-07-14 포항공과대학교 산학협력단 강화학습과 약동-약력학 모델을 이용한 연속 약물 투여량 결정 방법
CN113053508A (zh) * 2021-03-29 2021-06-29 深圳市科曼医疗设备有限公司 基于触控屏的交互控制方法及装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07124125A (ja) * 1993-11-04 1995-05-16 S R L:Kk 薬物投与解析システム
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
AU5219798A (en) * 1996-12-09 1998-07-03 Samuel David Gpi-ceruloplasmin, analogs thereof, and methods of use
BR0010316A (pt) * 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
JP2004510961A (ja) * 2000-09-15 2004-04-08 ビルコ・ビーブイビーエイ 疾患の処置のための薬物療法を最適化するシステムおよび方法
AU2004209286B2 (en) * 2003-02-01 2009-01-08 Baxter International Inc. Wireless medical data communication system and method
EP1642607A1 (en) * 2004-10-04 2006-04-05 Sanofi-Aventis Deutschland GmbH Dose display mechanism for a drug delivery device
JP2006155071A (ja) * 2004-11-26 2006-06-15 Toshiba Sumiden Medical Information Systems Corp 電子カルテ薬物療法指示実施システム
US20060183786A1 (en) * 2005-02-16 2006-08-17 Chi Mei Foundation Hospital Injectable long-acting analgesic composition comprising an ester derivative of ketorolac
CA2911569C (en) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
US8591454B2 (en) * 2008-11-10 2013-11-26 The Invention Science Fund I, Llc Administering a therapeutic agent with more than one taggant
SG181130A1 (en) 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Also Published As

Publication number Publication date
EP3309696A1 (en) 2018-04-18
AU2014287706B2 (en) 2017-10-05
MX2023000359A (es) 2023-02-13
KR20220065097A (ko) 2022-05-19
JP7060291B2 (ja) 2022-04-26
EA037962B1 (ru) 2021-06-16
JP2021061012A (ja) 2021-04-15
JP2022105022A (ja) 2022-07-12
MX2015017878A (es) 2016-09-14
IL243208A0 (en) 2016-02-29
CA2915472A1 (en) 2015-01-15
MX2020004112A (es) 2020-07-24
IL243208B (en) 2020-06-30
AU2017272293A1 (en) 2018-01-04
JP2019196352A (ja) 2019-11-14
BR112015031856A2 (pt) 2017-07-25
CN111508557A (zh) 2020-08-07
NZ715216A (en) 2020-07-31
EP3010681B1 (en) 2021-05-19
EA201690048A1 (ru) 2016-05-31
CA2915472C (en) 2023-09-19
AU2020202664A1 (en) 2020-05-14
ES2882832T3 (es) 2021-12-02
PH12015502800A1 (en) 2016-03-14
EP3879534A1 (en) 2021-09-15
GEP20196990B (en) 2019-07-10
AU2014287706A1 (en) 2016-01-21
MY176173A (en) 2020-07-24
EP3010681A4 (en) 2017-03-08
BR122020013811A8 (pt) 2022-08-30
WO2015006033A1 (en) 2015-01-15
CN105592973B (zh) 2020-06-19
KR20160022874A (ko) 2016-03-02
ZA201600100B (en) 2019-09-25
CL2015003641A1 (es) 2016-10-28
JP2016526542A (ja) 2016-09-05
SA521430246B1 (ar) 2022-09-14
IL274848A (en) 2020-07-30
BR122020013811A2 (ar) 2017-07-25
PL3010681T3 (pl) 2021-11-15
KR102352133B1 (ko) 2022-01-18
JP6813237B2 (ja) 2021-01-13
KR102296042B1 (ko) 2021-08-31
CN105592973A (zh) 2016-05-18
IL279313A (en) 2021-01-31
BR122022000127A8 (pt) 2022-08-30
GEP20186882B (en) 2018-07-25
IL279313B (en) 2022-08-01
PH12015502800B1 (en) 2016-03-14
BR122022000127A2 (ar) 2017-07-25
US20140379629A1 (en) 2014-12-25
KR20220011217A (ko) 2022-01-27
SG11201510515YA (en) 2016-01-28
UA118109C2 (uk) 2018-11-26
BR112015031856A8 (pt) 2022-08-30
AU2020202664B2 (en) 2022-06-02
EP3010681A1 (en) 2016-04-27
KR20210110736A (ko) 2021-09-08
JP7398031B2 (ja) 2023-12-14
CN111508557B (zh) 2024-03-26
AU2017272293B2 (en) 2020-01-23
KR102397974B1 (ko) 2022-05-13
MY195911A (en) 2023-02-27

Similar Documents

Publication Publication Date Title
AU2017272293B2 (en) Providing a pharmacokinetic drug dosing regimen
IN2015DN03826A (ar)
EP3581226A3 (en) Systems for delivery of therapeutic gas
MX2022012914A (es) Dispositivos y metodos para administracion y mezcla de farmaco, y entrenamiento de tecnicas apropiadas para ello.
MX2018013503A (es) Aparatos, métodos y sistemas para administrar medicamento utilizando kits de medicamento.
MX2020001369A (es) Sistema de analisis para el cuidado de un paciente.
Requena et al. Melomics music medicine (M 3) to lessen pain perception during pediatric prick test procedure.
SG11202106928PA (en) Medicine administering device and medicine administering system
MX2017008000A (es) Sistema de inyeccion de un solo uso.
EP3603709A4 (en) LIQUID MEDICINE ADMINISTRATION DEVICE AND ITS OPERATING PROCEDURE
MX2016000103A (es) Dispositivo de administracion de farmaco oral y metodos de uso del mismo.
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
EA202190596A2 (ru) Предоставление фармакокинетической схемы дозирования лекарственного средства
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
MA38685A1 (fr) Fourniture d'un régime de dosage de médicament pharmacocinétique
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
TH160649B (th) เครื่องและวิธีการสำหรับข้อกำหนดการให้ขนาดยาทางเภสัชจลนศาสตร์
TH160649A (th) เครื่องและวิธีการสำหรับข้อกำหนดการให้ขนาดยาทางเภสัชจลนศาสตร์
EP3925646A4 (en) LIQUID MEDICATION ADMINISTRATION DEVICE AND KIT
Vinas Cetirizine/hydroxyzine
Ramatillah et al. MANAGEMENT OF PAIN TREATMENT FOR POST ABDOMEN SURGERY PATIENTS FROM JANUARY TO MARCH 2015 IN ISLAMIC HOSPITAL CEMPAKA PUTIH, JAKARTA
MX2019004394A (es) Dispositivo para facilitar la administracion de un medicamento al pulmon por un cateter.
EP3646907A4 (en) DEVICE FOR ADMINISTRATING LIQUID MEDICATION AND METHOD FOR PRODUCING A DEVICE FOR ADMINISTRATING LIQUID MEDICATION
林彤 et al. Clinical Outcome of in Vitro Fertilization-embryo Transfer in Patients Over 40 Years from a Single Institution in Guangdong, China